E.i. Dupont De Nemours and Company

Other

The Dupont Merck Pharmaceutical Company

George A Boswell

Mimi Lifen Quan

Melvyn J Myers

Indawati De Lucca

Indawati DeLucca

Soo Sung Ko

Hui-Yin Li

Saul C Cherkofsky

Richard Gerald Wilde

Anthony J Cocuzza

Peter John Gillies

Jeffrey T Billheimer

James M Trzaskos

Anurag S Srivastava

Rosetta M Henderson

Spencer Drummond, Jr

Hollis S Kezar, Iii

Martin J Thoolen

William M Mackin

Janet S Kerr

A fuel air delivery circuit, system, and method for the intake of an internal combustion engine, that provides an enhanced pressure condition to a supplementary or auxiliary air fuel circuit or circuits in connection with a conventional fuel delivery passage or passages, such as, but not limited to, a main, needle, or other jet, injector port, manifold, plenum, or the like, to provide enhanced vaporization and mixture of the fuel and air, and delivery to an associated intake path, such as the bore of a carburetor, intake runner, or the like, to provide improved throttle response and acceleration, and additionally which supplementary circuit will automatically recharge with fuel when a triggering condition is present, such as under steady state and deceleration conditions.

Fuel air delivery circuit with enhanced response, fuel vaporization and recharge

A carburetor having a plurality of orifices at different locations adjacent to the sidewall of the airflow passage therethrough and connecting passages communicating the orifices with a fuel source, such that different airflow conditions through the airflow passageway will generate different negative pressure conditions in the respective orifices and connecting passages, such that fuel will be drawn to the airflow passageway through the orifice or orifices and connected passage or passages with the greatest negative pressure conditions therein, a primary operational result being fuel delivery capable of rapidly changing corresponding to rapidly changing airflow conditions in the airflow passageway corresponding to changing operating conditions.

Carburetor with primary and secondary fuel delivery circuits and methods of operation and installation of the same

Carburetor with primary and secondary fuel delivery circuits and methods

Apparatus for improving the vaporization of the intake charge for an internal combustion engine and for improving the induction or aspiration of the intake charge through the intake tract or passages of the an engine by generating suction from the intake charge flow through the intake tract and utilizing energy from back pressure and/or reverse pressure pulses flowing in the opposite direction in the intake tract to draw poorly or inadequately atomized or vaporized elements of the intake charge, raw fuel, and a condition known as 'reversion' from the intake tract into the apparatus, mix the collected elements, and discharge them back into the intake tract in a vaporized state to thereby improve the overall vaporization of the intake charge and reduce back pressure, reverse pulses, and the resultant reversion that can adversely affect induction as well as intake charge quality. The present invention also has utility in the exhaust tract or passages of an engine to capture and redirect exhaust generated back pressure back into to the exiting exhaust flow stream to prevent the back pressure from traveling on to the intake tract and contaminating the intake charge and interfering with induction, while also improving exhaust emissions and other parameters. Apparatus according to the present invention can be utilized at various locations in both the intake and exhaust tracts to operate in cooperation to provide enhanced induction flow throughout both tracts.

Apparatus for improving intake charge vaporization and induction for an

This invention provides amide compounds as inhibitors of acyl-Coenzyme A: cholesterol O-acyltransferase (ACAT), pharmaceutical compositions containing such compounds, processes for the preparation of such compounds, and the use of such compounds as antihypercholesterolemic and/or antiatherosclerotic agents.

Amides for the treatment of atherosclerosis

Novel imidazolinone derivatives of formula (I), which are useful as angiotensin II antagonists, are disclosed: ##STR1##

Angiotensin II receptor blocking imidazolinone derivatives

Antihypercholesterolemic bis-trifluoromethyl-substituted imidazolines

In a carburetor for an internal combustion engine, the improvement embodying an air flow surface disposed strategically in a venturi or air flow passageway of the carburetor, the air flow surface providing enhanced air flow velocity characteristics over a region thereof relative to the free stream velocity over the air flow surface, and an orifice located adjacent to the air flow surface in the vicinity of the region of enhanced air flow velocity so as to provide a vacuum signal through the orifice which corresponds substantially proportionally to the air flow velocity through the venturi or air flow passageway, the vacuum signal being usable for improving fuel delivery characteristics to the venturi as well as for other purposes. Several methods for incorporating the present invention into existing carburetor constructions are likewise disclosed.

Fuel delivery means for carburetors for internal combustion engines and

N-[2-(2-oxo-1-imidazolidinyl)ethyl]-3-phenylurea and analogs are useful for protecting against oxygen-derived free radical damage in mammals, by inducing endogenous antioxidant enzymes, including superoxide dismutase, in mammals.

N-(2-(2-oxo-1-imidazolidinyl)ethyl)-3-phenyl-urea and analogs as agents

N-oxide prodrug derivatives of 3-hydroxy morphinan and partial morphinan analgesics, agonist-antogonists, and narcotic antagonists are useful therapeutic entities which provide enhanced bioavailability of 3-hydroxy morphinans and partial morphinans from orally administered dosage forms.

N-oxide prodrug derivatives of 3-hydroxy morphinans and partial

N-oxide prodrug derivatives of 3-hydroxy morphinan and partial morphinan analgesics, agonist-antagonists, and narcotic antagonists are useful therapeutic entities which provide enhanced bioavailability of 3-hydroxy morphinans and partial morphinans from orally administered dosage forms.

Azapropazone can be used to prevent post-ischemic tissue damage in mammals.

Growing community of inventors

Wilmington, DE, United States of America

George A Boswell